Ardelyx (ARDX), a prominent biopharmaceutical entity, is poised to unveil its Q2 2025 earnings data, a highly anticipated event for the biopharma stock market. This announcement, scheduled for Monday, August 4th, after market close, will offer crucial insights into the company’s financial outlook and operational health, shaping investor analysis for the upcoming period.
Current market projections indicate that Ardelyx ARDX is expected to report an earnings per share (EPS) of ($0.12) for the second quarter of 2025. Simultaneously, analysts forecast the company’s revenue to reach $82.69 million for the same period, providing a key benchmark against which its actual performance will be measured.
Examining past performance, Ardelyx previously released its quarterly earnings on Thursday, May 1st. During that period, the biopharmaceutical firm reported an EPS of ($0.17), falling short of analysts’ consensus estimates of ($0.10) by a notable ($0.07). This prior performance offers context for the upcoming Q2 2025 Earnings release.
Delving deeper into the previous quarter’s financial specifics, Ardelyx recorded revenue of $74.11 million, which was below analysts’ expectations of $79.40 million. Despite this, the company demonstrated a robust 61.1% year-over-year increase in quarterly revenue. However, it also reported a negative return on equity of 34.45% and a negative net margin of 14.86%, highlighting areas for investor scrutiny.
The Ardelyx ARDX stock performance has also been a subject of interest for investor analysis. Shares opened at $4.33 on a recent Friday, reflecting current market sentiment. Over the past year, the company’s stock has fluctuated between a low of $3.21 and a high of $7.18, indicating volatility. Furthermore, the company holds a market capitalization of $1.04 billion, a price-to-earnings ratio of -19.68, and a beta of 0.68.
From a liquidity and solvency perspective, Ardelyx presents a debt-to-equity ratio of 1.04, a quick ratio of 3.81, and a current ratio of 4.12. The stock’s 50-day moving average price stands at $4.05, while its 200-day moving average price is $4.64, providing technical indicators for market analysis.
Institutional investor activity in Ardelyx ARDX has seen notable shifts. Major players like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. and Goldman Sachs Group Inc. have increased their positions, with the latter now owning over 2.3 million shares. Conversely, new positions were acquired by Focus Partners Wealth and Strs Ohio, collectively demonstrating significant institutional confidence, with 58.92% of the stock currently held by hedge funds and other large investors.
Several research firms have weighed in on Ardelyx, contributing to the financial outlook. Citigroup and HC Wainwright have maintained “buy” ratings, though some, like Raymond James Financial, adjusted ratings from “strong-buy” to “outperform.” Currently, Ardelyx ARDX holds an average rating of “Moderate Buy” from MarketBeat, with an average target price of $10.89, providing a consensus for investor analysis.
